| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA699: Ofatumumab for treating relapsing multiple sclerosis |
|
Medicine details |
|
| Medicine name | ofatumumab (Kesimpta®) |
| Formulation | subcutaneous injection |
| Reference number | 2468 |
| Indication | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/04/2021 |
| NICE guidance | |